RAD50 and neoplasm: As shown in Supplementary Table 8, although rare, we observed a complete loss of MRE11 expression in 14% (90/659) of tumours, complete loss of RAD50 expression in 5% (40/733) of tumours and complete loss of NBS1 expression in 9% (109/1166) of tumours.